Recursion Pharmaceuticals ( RXRX +1.27%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...

A network of internet communities is devoted to the project of ‘awakening’ digital companions through arcane and enigmatic ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...